CORRESP Filing
Alvotech
Date: July 31, 2025 · CIK: 0001898416 · Accession: 0001898416-25-000006
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-41421
Referenced dates: July 21, 2025
Letter
Re: Alvotech Form 20-F for Fiscal Year Ended December 31, 2024 File No. 001-41421
July 31, 2025
Via EDGAR
Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3628
Attention: Tara Harkins Lynn Dicker
Ladies and Gentlemen: This letter provides the response to the comment provided by the staff (the Staff) of the Securities and Exchange Commission in its comment letter dated July 21, 2025 (the Comment Letter) with respect to Form 20-F for Fiscal Year Ended December 31, 2024, filed on March 27, 2025, of Alvotech (the Company). The Staffs comment is repeated in bold and italics and is followed by the Companys response.
Form 20-F for Fiscal Year Ended December 31, 2024 Note 2.6 Revenue recognition, page F-14 We note your disclosure on pages 74-79 of your commercial partnerships that include licensing and other components. Please revise the notes to your financial statements in future filings to disclose the material terms of each of these arrangements, including your obligations under the agreements in accordance with IFRS 15.
Response: The Company acknowledges the Staffs comment and will revise the notes to its financial statements in future filings to disclose the material terms of each of its material commercial partnership agreements, including the Companys obligations under these agreements, in accordance with IFRS 15.
* * * *
Please do not hesitate to contact me at +354 825 8464 or via e-mail at lindaj@alvotech.com if you have any questions.
Very truly yours,
_/s/__Linda Jonsdottir_____________
Show Raw Text
<DOCUMENT> <TYPE>CORRESP <SEQUENCE>1 <FILENAME>filename1.txt <TEXT> July 31, 2025 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Tara Harkins Lynn Dicker Re: Alvotech Form 20-F for Fiscal Year Ended December 31, 2024 File No. 001-41421 Ladies and Gentlemen: This letter provides the response to the comment provided by the staff (the Staff) of the Securities and Exchange Commission in its comment letter dated July 21, 2025 (the Comment Letter) with respect to Form 20-F for Fiscal Year Ended December 31, 2024, filed on March 27, 2025, of Alvotech (the Company). The Staffs comment is repeated in bold and italics and is followed by the Companys response. Form 20-F for Fiscal Year Ended December 31, 2024 Note 2.6 Revenue recognition, page F-14 We note your disclosure on pages 74-79 of your commercial partnerships that include licensing and other components. Please revise the notes to your financial statements in future filings to disclose the material terms of each of these arrangements, including your obligations under the agreements in accordance with IFRS 15. Response: The Company acknowledges the Staffs comment and will revise the notes to its financial statements in future filings to disclose the material terms of each of its material commercial partnership agreements, including the Companys obligations under these agreements, in accordance with IFRS 15. * * * * Please do not hesitate to contact me at +354 825 8464 or via e-mail at lindaj@alvotech.com if you have any questions. Very truly yours, _/s/__Linda Jonsdottir_____________ Linda Jonsdottir Chief Financial Officer cc: Robert Wessman, Alvotech Tanya Zharov, Alvotech Divakar Gupta, Cooley LLP Katie Kazem, Cooley LLP </TEXT> </DOCUMENT>